1Georg-Burkhard K.Biosimilars-Science,status,and strategicperspective.European Journal of Pharmaceutics andBiopharmaceutics,2009,72:479-486.
2Schellekens H.Follow-on biologics:challenges of the“nextgeneration”.Nephrol Dial Transplant,2005,20(4):31-36.
3Evaluate Pharma-Biotech set to Dominate Drug Industry GrowthEP Vantage,20 09,6.[2012-02-27].http://www.evaluatepharma.com/universal/view.aspx?type=story&id=1887007&isEPVantage=yes.
4Simoens S,Verbeken G,Huys I.Market access of biosimilars:not only a cost issue.Oncologie,2011,13:218-221.
5Crommelin D,Bermejo T,.Bissig M.Biosimilars.generic versionsof the first gen-eration of therapeutic proteins:do they exist?.Contrib Nephrol,2005,149:287-294.
6Mellstedt H,Niederwieser D,Ludwig H.The challenge ofbiosimilars.Annals of Oncology,2008,19:411-419.
7EMA.Annex guideline on Similar Biological Medicinal ProductsContaining Biotechnology Derived Proteins as Active Substance:Non-clinical and Clinical Issues.Guidance on Similar MedicinalProducts Containing Somatropin.2006.[2012-02-27].http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_c ontent_000408.jsp&mid=WC0b 01ac058002958c&jsenabled=true.
8Simon D R.Biosimilars:current status and future directions.Expert Opin Biol Ther,2010,10(7):1-8.
9Dietger N,Stephan S.Biosimilar agents in oncology?haematolo-gy:from approval to practice.European Journal of Haematology,2010,86:277-288.
10McCamish M,Woollett G.Worldwide experience with biosimilardevelopment.Landes Bioscience,2011,3(2):212-220.
